Performant Healthcare Draws Buy Rating Despite Insider Sell-Off

Performant Healthcare, Inc. (NASDAQ:PHLT) is one of the 10 best high risk penny stocks to invest in.

Craig-Hallum maintains a Buy rating on the stock following a major stock sale by the company’s top executive.

Performant Healthcare Draws Buy Rating Despite Insider Sell-Off

A healthcare professional holding a device with innovative technology developed by the medical technology company.

Headquartered in Florida, Performant Healthcare, Inc. (NASDAQ:PHLT) is a U.S.-based payment integrity company offering technology-enabled audit, recovery, eligibility, customer care, and analytics services to health plans. With solutions capable of identifying and recovering improper payments and streamlining billing processes, the company serves clients like Medicaid, Medicare Advantage, and commercial insurers.

Performant Healthcare, Inc. (NASDAQ:PHLT) reported a 29% increase in revenue in Q1 2025, compared to the same quarter the previous year. The company has also revised its revenue guidance for 2025 from $133 to $135 million, signaling strong confidence in growth prospects. However, in a bold move, Director Lisa Im sold 180,867 shares of the company on June 4, 2025, in a transaction valued at $587,817.

Amid this significant change in insider transactions, Craig-Hallum reiterated a Buy rating on the stock, indicating confidence in the company’s future growth.

With a one-year median stock price forecast of $7, Performant Healthcare, Inc. (NASDAQ:PHLT)’s shares are available for interested investors at a price of $4 as of June 30, 2025.

While we acknowledge the potential of PHLT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Low Risk Dividend Paying Stocks for June 2025 and 10 Dividend Bargains Trading Below Insiders’ Prices

Disclosure. None.